WELL Health
Trending >

Concordia International of “limited value”, Canaccord Genuity says

Concordia International

Concordia InternationalStay away from Concordia International (Concordia International Stock Quote, Chart, News: TSX:CXR, Nasdaq:CXRX) says Canaccord Genuity analyst Neil Maruoka.

On Wednesday, Concordia announced that the U.K. Competition and Markets Authority (CMA) is investigating new issues in relation to the U.K. pharmaceutical sector, and that Concordia International Corp.’s international segment and certain of its products are part of the inquiry.

“We are working to better understand the CMA’s position and we will continue to work constructively to resolve these matters,” the company said.

Maruoka says this is just one more reason to stay away from this stock.

“We note that the investigation is in its early stages and the company continues to work with the CMA,” the analyst notes. “However, we believe this is another piece of negative news flow from the company’s International business (which follows UK regulatory changes for generic drugs and a separate investigation into pricing). Because these processes can take time and the resolution is uncertain, we expect this investigation could create another lingering overhang for the stock. “…we do not foresee any near-term fundamental catalysts that could turn the page for Concordia. Given Concordia’s high debt load and eroding performance, we continue to see limited value in the equity of the company.

In a research update to clients Wednesday, Maruoka maintained his “Sell” rating and one-year price target of (U.S.) $0.50 on Concordia International, implying a return of negative 59.4 per cent at the time of publication.

Maruoka thinks Concordia will generate EBITDA of $314.7-million on reveneu of $606.9-million in fiscal 2017. He expects those numbers will fall to EBITDA of $294.7-million on a topline of $552.6-million the following year.

More Cantech Life Sciences

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

About The Author /

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.
insta twitter facebook


Leave a Reply